Ke Shi
- Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research 12
- Virology top 2%
- HIV Research and Treatment 12
- Animal Science and Zoology top 2%
- Polymers and Plastics top 5%
- Molecular Biology top 5%
- RNA and protein synthesis mechanisms 22
- DNA and Nucleic Acid Chemistry 17
- CRISPR and Genetic Engineering 9
- RNA modifications and cancer 9
-
- Bacteriophages and microbial interactions 10
-
- Organic Electronics and Photovoltaics 9
- Journals
- Journal of Biological Chemistry (6 papers)Proceedings of the National Academy of Sciences (6 papers)Nucleic Acids Research (5 papers)
- Partner nations
- United StatesChinaSwitzerland
In The Last Decade
Ke Shi
116 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Infectious Diseases 2.7k
- Virology 248
- Animal Science and Zoology 336
- Polymers and Plastics 457
- Molecular Biology 2.2k
Countries citing papers authored by Ke Shi
This map shows the geographic impact of Ke Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Shi more than expected).
Fields of papers citing papers by Ke Shi
This network shows the impact of papers produced by Ke Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Shi. The network helps show where Ke Shi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ke Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 22 | |
| 5 | 2024 | 6 | |
| 6 | 2024 | 5 | |
| 7 | 2024 | 2 | |
| 8 | 2023 | 0 | |
| 9 | 2023 | 5 | |
| 10 | 2023 | 37 | |
| 11 | 2023 | 3 | |
| 12 | 2023 | 0 | |
| 13 | 2023 | 15 | |
| 14 | 2022 | 85 | |
| 15 | 2022 | 47 | |
| 16 | 2022 | 33 | |
| 17 | 2021 | 40 | |
| 18 | 2020 | 26 | |
| 19 | Structural basis of receptor recognition by SARS-CoV-2breakdown → | 2020 | 2514 |
| 20 | 2020 | 36 |
About Ke Shi
Ke Shi is a scholar working on Virology, Infectious Diseases and Molecular Biology, having authored 123 papers that have together received 5.8k indexed citations. Recurring topics across this work include RNA and protein synthesis mechanisms (22 papers), DNA and Nucleic Acid Chemistry (17 papers), HIV Research and Treatment (12 papers), SARS-CoV-2 and COVID-19 Research (12 papers), Bacteriophages and microbial interactions (10 papers), CRISPR and Genetic Engineering (9 papers), Organic Electronics and Photovoltaics (9 papers) and RNA modifications and cancer (9 papers). The work is most often cited by research in Infectious Diseases (2.7k citations), Virology (248 citations) and Animal Science and Zoology (336 citations). Ke Shi has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include Hideki Aihara, Gang Ye, Fang Li, Qibin Geng, Jian Shang, Yushun Wan, Ashley A. Auerbach, Chuming Luo, Jian Pei and M. Sundaralingam. Their work appears in journals such as Journal of Biological Chemistry, Proceedings of the National Academy of Sciences, Nucleic Acids Research, Structure and Journal of Molecular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.